Horizon Pharma, Inc. (HZNP) and Mallinckrodt, LLC the Pharmaceuticals business of Covidien (COV), announced that they have entered into a U.S. co-promotion agreement for DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
As per the terms of the agreement, Horizon granted Mallinckrodt the right to co-promote DUEXIS in United States through December 31, 2014 with the potential to renew for additional periods. Horizon and Mallinckrodt have consented that Mallinckrodt will promote to targeted physicians and is entitled to receive performance-based compensation.
The Mallinckrodt sales force is expected to begin promoting DUEXIS to physicians in August 2012. Horizon will continue to record all revenues for DUEXIS and will remain responsible for DUEXIS manufacturing, supply and regulatory activities.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.